Breaking News

Tweet TWEET

Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary

  Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice
  President, Treasurer and Corporate Secretary

    Seasoned biotech CFO with a wide range of public and VC-backed company
                                  experience

Rodman & Renshaw Global Investment Conference 2013

Business Wire

EXTON, Pa. -- August 26, 2013

Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company
focused on the development of innovative products for aesthetic, medical and
scientific applications, announced today the appointment of Greg Weaver as
Chief Financial Officer, Senior Vice President, Treasurer and Corporate
Secretary of the Company. Weaver replaces Declan Daly, who will leave the
company to reside full time in Ireland. Weaver and Daly will work side by side
through November 2013 to assure a smooth financial leadership transition.

Weaver brings more than thirty years of strategic and financial management
experience to Fibrocell, where he will be responsible for the company's
day-to-day financial operations at the corporate offices in Exton, Pa. He
joins Fibrocell from oncology drug development company Celsion Corp. where he
served as chief financial officer after serving six years on Celsion's board
of directors.

Prior to Celsion, Weaver served as CFO for six other biotechnology companies,
including Poniard Pharmaceuticals, Talyst, Inc., Sirna Therapeutics, Nastech
Pharmaceutical Co., Ilex Oncology and Prism Technologies and consulted for
countless others. Over the course of his career, he has managed corporate and
situation-specific financing strategies, dramatically increased multiple
market cap valuations and overseen multiple product and service revenue
channels, and manufacturing supply relationships.

“I am confident that Greg’s wealth of experience working with growth companies
will provide Fibrocell with a strong foundation for continued expansion," said
David Pernock, Chairman and Chief Executive Officer of Fibrocell Science.

“It excites me that Fibrocell has a presence in aesthetics and that they are
steadily expanding into medical markets to address unmet needs,” Weaver said.
“I am eager to join the Fibrocell team and am confident that my experience
growing biotechnology companies will help catapult the Company toward its
future milestones.”

Weaver will join Mr. Pernock at the Rodman & Renshaw 15^th Annual Global
Investor Conference for the Company’s presentation on Tuesday, September 10 at
11:15 a.m.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
focused on the development of innovative products for aesthetic, medical and
scientific applications. Fibrocell Science is committed to advancing the
scientific, medical and commercial potential of autologous skin and tissue, as
well as its innovative cellular processing technology and manufacturing
excellence. For additional information, please visit www.fibrocellscience.com.

Contact:

Investor Relations
The Ruth Group
Zack Kubow/Melanie Sollid-Penton
646-536-7020/7023
zkubow@theruthgroup.com
msollid@theruthgroup.com
or
Media
Marina Maher Communications, LLC
Heather Adamson, 212-485-6806
hadamson@mahercomm.com